Treatment Study for Patients with Newly Diagnosed B-Lymphoblastic Leukemia or B-Lineage Lymphoblastic Lymphoma

Clinical Trial Title

Treatment of patients with newly diagnosed standard risk B-lymphoblastic leukemia (B-ALL) or localized B-lineage lymphoblastic lymphoma (B-LLy).

Clinical Trial Protocol Description:

To determine if a maintenance regimen containing weekly oral methotrexate at 40mg/m2/week will result in an improved disease free survival (DFS) compared to that containing weekly oral methotrexate at 20mg/m2/week in the average risk subset of patients with standard risk B-ALL.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have newly diagnosed NCI standard risk B-ALL or B-LLy Murphy Stages I or II.
  • Have an initial white blood cell count < 50,000/uL.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Mary Lou Schmidt, MD

Contact Information

Rush Cancer Center Clinical Trials Office